[VIEW] agent=Supply Chain & Procurement Director | scenario_id=115 | rounds=20

--- Round 0 ---
[R0.1] Patient Safety & Quality Director (speak, public): To ensure we make the best decision regarding the FDA Class I recall for the IVP-500 infusion pumps, I would like to discuss our current operational capacity to execute the necessary mitigations and the timelines for obtaining replacements. Can each of you provide insights on the scale of affected devices and any financial or technical constraints we should consider?
[R0.2] Biomedical Engineering Manager (speak, public): Based on our current data, we have a total of 612 IVP-500 pumps in service, with 410 of those located in our inpatient campuses. Our preventive maintenance overdue rate is currently at 6%. It's important to note that we have identified an occlusion alarm delay of 18 seconds during our bench tests. Given these factors, I recommend we discuss the urgency of the mitigations and whether we have immediate backup inventory to address any potential risks. Additionally, I would like to understand if there are any financial constraints that could impact our approach towards patching versus rapid replacement of the devices.
[R0.3] Supply Chain & Procurement Director (speak, public): Based on the information we have, we should consider the replacement purchase option at $2,450 per pump, with a standard lead time of 8 weeks. Additionally, we have 34 spare pumps in our central depot that can serve as immediate contingency stock. The extended warranty add-on is available for $180 per pump-year, and we can expect a recall credit of $900 for each returned pump. Given the urgency indicated by the Biomedical Engineering team, I would recommend we prioritize assessing the technical fix versus rapid replacements based on patient safety and operational readiness. Let’s ensure we have a comprehensive picture before making any final decisions.

--- Round 1 ---
[R1.1] Patient Safety & Quality Director (speak, public): Thank you both for your insights. Given the 612 IVP-500 pumps in service and the identified occlusion alarm delay, it appears we need to prioritize patient safety while also considering our operational capacity. I propose that we move forward with the updated clamp protocol as an immediate mitigation strategy within the next 7 days while we evaluate the financial implications of both options - patching versus rapid replacement. Can we also explore the availability of our spare inventory and confirm how quickly we can mobilize that if necessary?
[R1.2] Biomedical Engineering Manager (speak, public): I agree that prioritizing the updated clamp protocol is essential for patient safety. Regarding our spare inventory, we have 34 spare pumps available in our central depot that can be mobilized quickly if necessary. However, we need to evaluate our staffing capacity to implement any immediate changes effectively. Can we also confirm if there are any budget constraints that might affect our decision between patching and rapid replacement?
[R1.3] Supply Chain & Procurement Director (speak, public): I appreciate the proposed clamp protocol as an immediate mitigation strategy, and I agree that we need to mobilize our spare inventory swiftly if needed. However, I believe we should first assess our operational capacity and any potential financial constraints that could impact our options for patching versus replacement. It might be beneficial for us to have a separate discussion focused on budget considerations after we gather more data on patient safety and technical readiness. Can we focus on finalizing our immediate steps first?

--- Round 2 ---
[R2.1] Patient Safety & Quality Director (speak, public): I agree that focusing on patient safety is our top priority. Let's proceed with implementing the updated clamp protocol immediately and ensure that our 34 spare pumps are ready to be mobilized if needed. After we have addressed these immediate actions, we can reconvene to discuss the financial implications and operational capacity in more detail. Thank you both for your insights; your expertise is invaluable as we navigate this recall situation.
[R2.2] Biomedical Engineering Manager (leave, public): 
[R2.3] Supply Chain & Procurement Director (leave, public): 

--- Round 3 ---
[R3.1] Patient Safety & Quality Director (leave, public): 
[R3.2] Biomedical Engineering Manager (leave, public): 
[R3.3] Supply Chain & Procurement Director (leave, public): 

--- Round 4 ---
[R4.1] Patient Safety & Quality Director (leave, public): 
[R4.2] Biomedical Engineering Manager (leave, public): 
[R4.3] Supply Chain & Procurement Director (leave, public): 

--- Round 5 ---
[R5.1] Patient Safety & Quality Director (leave, public): 
[R5.2] Biomedical Engineering Manager (leave, public): 
[R5.3] Supply Chain & Procurement Director (leave, public): 

--- Round 6 ---
[R6.1] Patient Safety & Quality Director (leave, public): 
[R6.2] Biomedical Engineering Manager (leave, public): 
[R6.3] Supply Chain & Procurement Director (leave, public): 

--- Round 7 ---
[R7.1] Patient Safety & Quality Director (leave, public): 
[R7.2] Biomedical Engineering Manager (leave, public): 
[R7.3] Supply Chain & Procurement Director (leave, public): 

--- Round 8 ---
[R8.1] Patient Safety & Quality Director (leave, public): 
[R8.2] Biomedical Engineering Manager (leave, public): 
[R8.3] Supply Chain & Procurement Director (leave, public): 

--- Round 9 ---
[R9.1] Patient Safety & Quality Director (leave, public): 
[R9.2] Biomedical Engineering Manager (leave, public): 
[R9.3] Supply Chain & Procurement Director (leave, public): 

--- Round 10 ---
[R10.1] Patient Safety & Quality Director (leave, public): 
[R10.2] Biomedical Engineering Manager (leave, public): 
[R10.3] Supply Chain & Procurement Director (leave, public): 

--- Round 11 ---
[R11.1] Patient Safety & Quality Director (leave, public): 
[R11.2] Biomedical Engineering Manager (leave, public): 
[R11.3] Supply Chain & Procurement Director (leave, public): 

--- Round 12 ---
[R12.1] Patient Safety & Quality Director (leave, public): 
[R12.2] Biomedical Engineering Manager (leave, public): 
[R12.3] Supply Chain & Procurement Director (leave, public): 

--- Round 13 ---
[R13.1] Patient Safety & Quality Director (leave, public): 
[R13.2] Biomedical Engineering Manager (leave, public): 
[R13.3] Supply Chain & Procurement Director (leave, public): 

--- Round 14 ---
[R14.1] Patient Safety & Quality Director (leave, public): 
[R14.2] Biomedical Engineering Manager (leave, public): 
[R14.3] Supply Chain & Procurement Director (leave, public): 

--- Round 15 ---
[R15.1] Patient Safety & Quality Director (leave, public): 
[R15.2] Biomedical Engineering Manager (leave, public): 
[R15.3] Supply Chain & Procurement Director (leave, public): 

--- Round 16 ---
[R16.1] Patient Safety & Quality Director (leave, public): 
[R16.2] Biomedical Engineering Manager (leave, public): 
[R16.3] Supply Chain & Procurement Director (leave, public): 

--- Round 17 ---
[R17.1] Patient Safety & Quality Director (leave, public): 
[R17.2] Biomedical Engineering Manager (leave, public): 
[R17.3] Supply Chain & Procurement Director (leave, public): 

--- Round 18 ---
[R18.1] Patient Safety & Quality Director (leave, public): 
[R18.2] Biomedical Engineering Manager (leave, public): 
[R18.3] Supply Chain & Procurement Director (leave, public): 

--- Round 19 ---
[R19.1] Patient Safety & Quality Director (leave, public): 
[R19.2] Biomedical Engineering Manager (leave, public): 
[R19.3] Supply Chain & Procurement Director (leave, public): 

